Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 5.60 -0.05 (0.89%)
Day High: 5.81
Day Low:  5.41
Volume:    59,829,500
4:00 PM ET
Apr 29, 2016

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

Mar 15, 2016 / 1:00 PM PT